These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30229374)

  • 21. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
    Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
    Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An elicitation of utility for quality of life under prospect theory.
    Attema AE; Brouwer WB; l'Haridon O; Pinto JL
    J Health Econ; 2016 Jul; 48():121-34. PubMed ID: 27179198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating a Preference-Based Single Index Measuring the Quality-of-Life Impact of Self-Management for Diabetes.
    Rowen D; Labeit A; Stevens K; Elliott J; Mulhern B; Carlton J; Basarir H; Brazier J
    Med Decis Making; 2018 Aug; 38(6):699-707. PubMed ID: 29957107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inquiry into the relationship between equity weights and the value of the QALY.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2012 Dec; 15(8):1119-26. PubMed ID: 23244815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation.
    Witiw CD; Tetreault LA; Smieliauskas F; Kopjar B; Massicotte EM; Fehlings MG
    Spine J; 2017 Jan; 17(1):15-25. PubMed ID: 27793760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations.
    Johnson FR; Scott FI; Reed SD; Lewis JD; Bewtra M
    Value Health; 2019 Jun; 22(6):684-692. PubMed ID: 31198186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysing risk attitudes to time.
    Oliver A; Cookson R
    Health Econ; 2010 Jun; 19(6):644-55. PubMed ID: 19424992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theoretical bounds on the value of improved health.
    Herrera-Araujo D; Hammitt JK; Rheinberger CM
    J Health Econ; 2020 Jul; 72():102341. PubMed ID: 32531565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Setting Dead at Zero: Applying Scale Properties to the QALY Model.
    Roudijk B; Donders ART; Stalmeier PFM
    Med Decis Making; 2018 Aug; 38(6):627-634. PubMed ID: 29629848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of obesity on cost per quality-adjusted life years gained following anterior cervical discectomy and fusion in elective degenerative pathology.
    Chotai S; Sielatycki JA; Parker SL; Sivaganesan A; Kay HL; Stonko DP; Wick JB; McGirt MJ; Devin CJ
    Spine J; 2016 Nov; 16(11):1342-1350. PubMed ID: 27394664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relative value of different QALY types.
    Lancsar E; Gu Y; Gyrd-Hansen D; Butler J; Ratcliffe J; Bulfone L; Donaldson C
    J Health Econ; 2020 Mar; 70():102303. PubMed ID: 32061405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of total shoulder arthroplasty: a prospective health economic study using real-world data.
    Grobet CE; Glanzmann MC; Eichler K; Rickenbacher D; Meier F; Brunner B; Audigé L
    J Shoulder Elbow Surg; 2021 Sep; 30(9):1998-2006. PubMed ID: 33774171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of an integrated 'fast track' rehabilitation service for multi-trauma patients: A non-randomized clinical trial in the Netherlands.
    Wijnen BFM; Hemmen B; Bouman AIE; van de Meent H; Ambergen T; Brink PRG; Seelen HAM; Evers SMAA
    PLoS One; 2019; 14(3):e0213980. PubMed ID: 30901353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.
    Beresniak A; Medina-Lara A; Auray JP; De Wever A; Praet JC; Tarricone R; Torbica A; Dupont D; Lamure M; Duru G
    Pharmacoeconomics; 2015 Jan; 33(1):61-9. PubMed ID: 25230587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Problems and solutions in calculating quality-adjusted life years (QALYs).
    Prieto L; Sacristán JA
    Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
    Theriou C; Fielden CA; Kitterick PT
    Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC; Brown MM; Menezes A; Busbee BG; Lieske HB; Lieske PA
    Ophthalmology; 2013 Dec; 120(12):2367-2376. PubMed ID: 24246824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.